> Research Use Only Disclaimer: All peptides discussed in this article are sold strictly for laboratory and scientific research purposes. They are not approved for human use by the FDA or any regulatory authority. This content does not constitute medical advice. Consult a licensed healthcare provider for any health concerns.
The hypothalamic-pituitary-gonadal (HPG) axis governs testosterone production and reproductive function in men through a tightly regulated cascade: GnRH from the hypothalamus stimulates LH and FSH from the pituitary, which in turn drive testosterone synthesis in Leydig cells and spermatogenesis in Sertoli cells. Several peptides act as modulators of this axis or downstream pathways, making them valuable tools for endocrinology and reproductive biology research.
This guide covers the most studied peptides in men's hormonal health research — their mechanisms, evidence base, and sourcing considerations.
The HPG Axis: Research Foundation
- •Kisspeptin neurons in the hypothalamus are the master upstream regulators of GnRH release
- •GnRH (Gonadorelin) pulses drive pituitary LH and FSH secretion
- •LH stimulates Leydig cells → testosterone synthesis
- •FSH supports Sertoli cells → spermatogenesis
- •Testosterone exerts negative feedback on GnRH and LH
---
1. Kisspeptin-10 — Upstream HPG Axis Activator
Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (C-terminal amide)
Mechanism: Endogenous neuropeptide that binds KISS1R (GPR54) on GnRH neurons, triggering GnRH release. Acts as the principal upstream activator of the reproductive axis.
Key research findings:
- •Acute kisspeptin-10 administration produced robust LH surges in both male and female subjects
- •Kisspeptin restored LH pulsatility in hypogonadotropic hypogonadism models
- •Kisspeptin neurons integrate metabolic and reproductive signaling
- •Stimulation of endogenous testosterone production in clinical research settings
Research applications: HPG axis studies, LH secretion dynamics, GnRH neuron biology, hypogonadotropic hypogonadism models.
Sourcing note: Requires C-terminal amide for receptor binding — confirm this modification on COA. MW: 1,302.5 Da. Purity ≥98% HPLC. Compare prices at /peptide/kisspeptin-10.
---
2. CJC-1295 (with and without DAC)
Mechanism: Growth hormone-releasing hormone (GHRH) analog that stimulates GH pulse amplitude. The DAC form extends half-life from ~30 minutes to ~6–8 days via albumin binding. GH promotes IGF-1, which supports Leydig cell function.
Key research findings:
- •CJC-1295 without DAC produced significant GH pulses in pharmacokinetic research (PMID: 16352683)
- •Extended half-life with DAC form showed sustained IGF-1 elevation (PMID: 16352683)
- •IGF-1 upregulation via GH axis relevant to Leydig cell support and body composition
Research applications: GH axis studies, somatotrope physiology, IGF-1 dynamics, body composition research models.
Sourcing note: Available as CJC-1295 no DAC (short half-life) or with DAC (long half-life) — confirm which you're ordering. MW: ~3,367 Da (no DAC). Purity ≥98% HPLC, MS confirmation.
---
3. Ipamorelin — GH Secretagogue
Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2 (pentapeptide)
Mechanism: Selective ghrelin receptor (GHSR-1a) agonist that stimulates GH release without meaningfully affecting cortisol, prolactin, or ACTH — high selectivity makes it a preferred research tool.
Key research findings:
- •Robust, dose-dependent GH release without significant cortisol elevation (PMID: 9665665)
- •High selectivity for GHSR-1a vs. other hormone systems (PMID: 9665665)
- •Low tachyphylaxis profile suitable for chronic administration studies
Research applications: GH secretagogue research, GHSR biology, GH pulse pharmacology.
Sourcing note: Contains non-standard amino acids (Aib, D-2Nal). MS must confirm correct MW of 711.9 Da. Purity ≥98% HPLC.
---
4. PT-141 (Bremelanotide)
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (cyclic heptapeptide)
Mechanism: Melanocortin receptor agonist at MC3R and MC4R. Acts centrally via hypothalamic pathways to promote sexual arousal, independent of PDE5 inhibition.
Key research findings:
- •Produced erections via central (not peripheral vascular) mechanism in preclinical models (PMID: 12130688)
- •MC4R activation linked to pro-erectile central pathways (PMID: 12130688)
Research applications: Melanocortin receptor biology, sexual behavior neuroscience, central erectile pathway studies.
Sourcing note: Cyclic peptide — MS must confirm cyclic structure (MW: 1,025.2 Da). Purity ≥98% HPLC. Compare prices at /peptide/pt-141.
---
5. Gonadorelin (GnRH)
Sequence: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (decapeptide, C-terminal amide)
Mechanism: Endogenous GnRH. Pulsatile administration drives pituitary LH and FSH secretion; continuous administration causes receptor desensitization and testosterone suppression.
Key research findings:
- •Pulsatile gonadorelin administration restored spermatogenesis in Kallmann syndrome models
- •Established dose-response relationship for LH secretion
- •Standard tool for testing pituitary GnRH receptor responsiveness
Research applications: GnRH receptor pharmacology, pituitary stimulation tests, HPG axis modeling.
Sourcing note: N-terminal pGlu (pyroglutamic acid) and C-terminal amide both required for receptor binding — confirm on COA. MW: 1,182.3 Da. Purity ≥98% HPLC.
---